Last $1.20 USD
Change Today +0.03 / 2.56%
Volume 278.4K
ARQL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Snapshot

Open
$1.16
Previous Close
$1.17
Day High
$1.20
Day Low
$1.13
52 Week High
09/27/13 - $2.94
52 Week Low
09/18/14 - $1.13
Market Cap
75.3M
Average Volume 10 Days
151.1K
EPS TTM
$-0.41
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (ARQL)

arqule inc (ARQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (ARQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover therapeutic compounds that selectively inhibit certain kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

61 Employees
Last Reported Date: 08/5/14
Founded in 1993

arqule inc (ARQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Chief Operating Officer, Principal...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.3K
Compensation as of Fiscal Year 2013.

arqule inc (ARQL) Key Developments

ArQule Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Confirms Earnings Guidance for the Year 2014; Provides Operational Update

ArQule Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $6,339,000 or $0.10 per share, compared with a net loss of $6,786,000 or $0.11 per share for the second quarter of 2013. The company reported total revenues of $2,901,000 compared with $4,436,000 for the second quarter of 2013. Loss from operations was $6,406,000 against $6,844,000 for the same period a year ago. The $1.5 million revenue decrease in the three months ended June 30, 2014 is primarily due to revenue decreases of $0.9 million from the company's Daiichi Sankyo tivantinib program and $0.6 million from the company's Daiichi Sankyo ARQ 092 agreement that ended in June 2013. For the six months, the company reported a net loss of $13,480,000 or $0.22 per share, compared with a net loss of $12,561,000 or $0.20 per share, for the six-month period ended June 30, 2013. Revenues were $5,577,000 compared with $10,097,000 for the six months ended June 30, 2013. Loss from operations was $13,711,000 against $12,764,000 for the same period a year ago. The $4.5 million revenue decrease in the six months ended June 30, 2014 is primarily due to revenue decreases of $1.4 million from the company's Daiichi Sankyo tivantinib program, $1.8 million of other revenue related to a one-time research project in the six months ended June 30, 2013 and $1.3 million from the company's Daiichi Sankyo ARQ 092 agreement that ended in June 2013. For fiscal 2014, the company confirmed its 2014 financial guidance. For the year, the company expects net use of cash to range between $35 and $38 million. Revenues are expected to range between $8 and $10 million. Net loss is expected to range between $30 and $33 million, and net loss per share is expected to range between $0.48 and $0.52. The company announced operational update. Approximately 110 clinical sites are now enrolling patients in the Phase 3 METIV-HCC trial of tivantinib in second line hepatocellular carcinoma (HCC), with the goal of recruiting approximately 300 patients. Seven presentations on tivantinib were highlighted at the 2014 ASCO Annual Meeting, including three from trials being sponsored by the National Institutes of Health. The dose escalation portions of Phase 1 clinical trials with ARQ 092, an orally bioavailable, non-ATP competitive inhibitor of Akt, and ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor (FGFR) activity, are concluding, and biomarker-driven Phase 1b expansion cohorts in these trials are about to be initiated. Data with these compounds are planned for presentation in November 2014 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

ArQule Inc. to Report Q2, 2014 Results on Aug 05, 2014

ArQule Inc. announced that they will report Q2, 2014 results at 7:00 AM, US Eastern Standard Time on Aug 05, 2014

ArQule Inc., Q2 2014 Earnings Call, Aug 05, 2014

ArQule Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $1.20 USD +0.03

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.27 USD +0.08
Curis Inc $1.52 USD -0.04
Cytokinetics Inc $4.14 USD +0.28
Exelixis Inc $1.70 USD -0.02
Rigel Pharmaceuticals Inc $2.18 USD -0.05
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.6x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.